NCT01100437 - Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Chronic Pain

Interventions

DRUG

EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush

Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily

DRUG

EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole

EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution

Trial Locations (1)

84106

Lifetree Clinical Research, Salt Lake City